Pharsight

Drugs that contain Osilodrostat Phosphate

1. List of Isturisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(3 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(5 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(12 years from now)

Do you want to check out ISTURISA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

NCE-1 date: 2024-03-06

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

16

United States

8

Japan

7

European Union

5

Korea, Republic of

5

China

4

Spain

4

Mexico

3

Australia

EA

3

EA

3

Israel

3

Croatia

3

Canada

3

Denmark

3

Tunisia

3

Peru

3

Cyprus

3

Singapore

3

Portugal

3

Poland

3

Slovenia

3

Hungary

3

Taiwan

3

Lithuania

2

Ecuador

2

New Zealand

2

Chile

2

Philippines

2

Morocco

2

Norway

2

Argentina

2

Brazil

2

South Africa

1

Luxembourg

IB

1

IB

1

Netherlands

1

Malaysia

1

ME

1

Jordan

1

Ukraine

1

Russia

1

Hong Kong

1

Guatemala

1

RS

1

Turkey

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic